SUMMER 2025

accelerator

DRIVING IMPACT

for myeloma patients

MULTIPLE MYELOMA
Research Foundation

A MESSAGE FROM THE CEO

> “With more and more uncertainty surrounding future government funding for cancer research and biopharma’s investment in myeloma, **the MMRF’s leadership is more vital than ever.”**

Dear friends,

For nearly three decades, the Multiple Myeloma Research Foundation® (MMRF®) has been unwavering in its mission: to accelerate a cure for every myeloma patient. Thanks to the dedication of our community and partners, we’ve made remarkable strides, helping bring more than 15 FDA-approved therapies to market, advancing our understanding of disease biology through cutting-edge research, and empowering patients through robust education and support programs.

Today, patients are living longer and with greater quality of life. But our work is far from done.

Myeloma remains incurable, and not all patients benefit equally from current treatments. Many still face barriers to accessing the care they need. A growing misconception that myeloma is no longer a pressing medical issue due to the number of available therapies has led to a troubling decline in biopharma investment and federal research funding.

That’s why we’re taking bold action. This year, we’re investing $7 million through our Myeloma Investment Fund® to support innovative, early-stage treatments that might otherwise go unfunded.

We’re also unlocking the power of data. Research too often happens in silos, slowing progress. Through initiatives like the MMRF CoMMpass℠ Study and Immune Atlas, we’ve made patient data openly available to researchers worldwide. Now, we’re taking the next step with the launch of the MMRF Virtual Lab®, a groundbreaking platform offering the most comprehensive open-source data in myeloma research — all in one place.

This fall, we’ll also launch a new clinical trial through our Horizon Clinical Trials Program, focused on high-risk, newly diagnosed patients.

Nearly 30 years in, our urgency has only grown. With more and more uncertainty surrounding future government funding for cancer research and biopharma’s investment in myeloma, the MMRF’s leadership is more vital than ever. We remain committed to pushing the boundaries of what’s possible — focusing our efforts where they can have the greatest impact for patients.

Thank you for standing with us.

Michael Andreini
President and Chief Executive Officer
Multiple Myeloma Research Foundation®

Contents

Advancing
New Therapies

IMPACT OF MIF®
(Since 2019)

$23M
Invested

20
Companies in Portfolio

6
Treatments Advanced to the Clinic

The MMRF is the only patient-centered research organization focused on accelerating new therapies for myeloma. Our work and research deliver real-world impact, advancing treatments and generating data that improve patients' lives. Since the MMRF was founded, more than 15 drugs for myeloma have been FDA-approved; we've opened nearly 100 clinical trials and raised over $600M for research; and survival, which was 35% when we started, has nearly doubled to 63%. But despite this progress, many patients are still unable to access or benefit from advances in treatment. We are determined to drive the field forward, discover new treatments, ensure that all patients get the care they need to improve their outcomes, and take the lead in the pursuit of a cure. To us, this work has never been more critical.

Myeloma Investment Fund® (MIF)

The MIF is the first and only mission-driven philanthropy fund accelerating a cure for myeloma. Unlike any other organization in the myeloma space, the MIF provides both financial and strategic support to biotechnology companies who are developing transformative approaches to myeloma treatment — therapies designed to be more accessible, more tolerable, and more effective, especially for relapsed patients who are out of options.

MIF investments provide funding at a pivotal point in the drug development process, when early breakthroughs are at risk of stalling due to lack of funding or direction. By stepping in at this decisive phase, we help bridge the gap between research and real-world application. The MIF also connects these companies with key research and clinical partners who help validate their approach and improve the chance that these therapies will succeed. At a time when early-stage funding is harder to secure than ever, this early support is essential to attract further investment and ensure that the most promising ideas don't get left behind.

At the start of 2025 we invested in **Umoja Biopharma**, a pioneer in in vivo CAR T-cell therapies. Umoja's flagship VivoVec platform generates CAR T cells inside the patient's body, bypassing the need for CAR T cell production in a lab. VivoVec aims to simplify CAR T-cell therapies, increase their effectiveness, decrease their cost, and speed up the delivery of CAR T to patients. The company is currently working on an exciting new program in multiple myeloma.

In May, the MIF invested in **Stylus Medicine**, another company developing transformative in vivo therapies.

> **"Stylus was established to reimagine how genetic medicines reach patients...** By removing the complexity of ex vivo and viral manufacturing, we will dramatically simplify patient treatment. Our goal is to bring the life-saving promise of genetic medicines to every patient in need, starting with CAR T therapies."
>
> **— Emile Nuwaysir, Ph.D.**
> Chairman and Chief Executive Officer of Stylus

What is in vivo CAR T-cell therapy?

In vivo CAR T-cell therapy is a novel treatment that engineers CAR T cells directly in a patient's body, as opposed to the traditional ex vivo method which extracts cells from the patient's body and genetically modifies them in a lab to produce CAR T cells.

While in vivo CAR T therapies are still being explored, they promise faster, affordable, effective care for more myeloma patients.

MIF® PARTNER PROFILE

Andrew Scharenberg, MD

Umoja Biopharma: Pioneering In Vivo CAR T-Cell Therapies

Andy Scharenberg is the Co-Founder and CEO of Umoja Biopharma, a pioneer in in vivo CAR T-cell therapy. We spoke with him about Umoja's innovative approach, its partnership with the MIF, and how the MMRF is helping accelerate transformative treatments for myeloma.

Can you tell us about Umoja and your work in myeloma?

We started Umoja in 2019 with a big goal: to make CAR T-cell therapy easier to use and accessible to more patients. At the time, only about 1 in 10 patients could receive CAR T. Today, that number is closer to 1 in 5. But that's still not good enough.

While CAR T-cell therapy is an opportunity for patients, it can also be complicated. Doctors have to take your immune cells out, send them to a lab to be changed, and then return them to your body. This takes time, is expensive, and can be hard for patients to access. At Umoja, we're working on a new approach called in vivo CAR T-cell therapy where the therapy happens inside your body instead. Our treatment is delivered through a simple infusion that helps the immune system recognize and attack the cancer — like how it fights off a virus.

Why is CAR T so hard for patients to get and how is Umoja trying to fix that?

The current CAR T process can take up to 3 months and usually requires multiple trips to a major cancer center. During that time, the cancer can grow, and patients may need other treatments that can make CAR T less effective.

That's why we're working to replace that long, complicated process with a much faster one. Our vision is that, after being diagnosed, you could get an infusion at your local hospital that same day — no chemo, no travel, no waiting.

Why are you focusing on multiple myeloma?

CAR T works well in blood cancers, like multiple myeloma. Since we're introducing a new way to deliver it, we're starting with a cancer where the science is strong and the treatment is already proven to work. That gives us the best chance to help patients quickly.

How does early funding from the MIF help?

Developing a new treatment can take years — often 10 or more. Some investors can't wait that long, which makes it hard for new ideas to get started. That's why support from the MIF and MMRF is so important. They're willing to invest early and give promising treatments the time they need to reach their full potential. The MMRF's backing helps companies like ours take those critical first steps.

Beyond funding, how else do the MMRF and MIF help?

The MMRF and the MIF bring deep knowledge of myeloma and strong connections across the medical and research community. Because they're trusted by doctors and scientists, their support helps open doors. When others see that the MIF believes in what we're doing, it gives them confidence that our work is promising and based on solid science. That support helps us move faster and bring new treatments to patients sooner.

Optimizing
Current Treatments

In the past few decades, we've seen incredible progress as new treatments have improved outcomes for myeloma patients. But not all patients benefit, and we know that patients and physicians still face complex questions around the most effective treatment options. We're advancing a clinical research strategy that can provide meaningful insights on the best treatment approaches and evolve with the needs of patients and the research community over time.

We also know that collaboration and partnership are key to fueling innovation and shaping a future that is free of myeloma, which is why we're sharing data from our research initiatives and creating connections between researchers, biopharma companies, and physicians. Together, we can gain a better understanding of myeloma and develop more effective therapies for patients. By making our data available to researchers everywhere, the MMRF is paving the way for faster, more informed approaches to myeloma.

Horizon Clinical Trials Program

In late 2024, the MMRF launched the Horizon Clinical Trials Program through the Multiple Myeloma Research Consortium® (MMRC), a collaborative research network of leading myeloma treatment centers. Horizon operates through MMRC partners and uses an innovative trial design called an adaptive platform, which makes it possible to test multiple therapies at the same time to determine the best combination, sequence, and duration of treatment to get the best outcomes for patients. The adaptive design also allows researchers to work together and move faster than they can in a traditional clinical trial model.

For the first trial within the Horizon program (**Horizon One**), we are enrolling patients with relapsed and refractory myeloma across 13 sites to study dosing approaches with Tecvayli® (teclistamab), a bispecific antibody treatment. Horizon One will include over 100 patients: the study will operate 2-3 arms, with 30 patients per arm and another 60 patients in the control group. The goal is to determine the most effective dose and schedule of Tecvayli to maximize response and minimize side effects; after one year of treatment with Tecvayli, patients who have a good response will be randomized into one of three groups: continuing the treatment per the drug's current dosing; continuing with a less frequent dose; or stopping therapy altogether.

The second platform trial of the program, **Horizon Two**, is scheduled to launch in late 2025 and will enroll high-risk, newly diagnosed patients. We will start with a 4-treatment combination and a BCMA bispecific antibody therapy, and the first sites will be open to screen patients by the fall.

Horizon builds on our commitment to ensuring that our research initiatives reflect the real-world myeloma patient population, including groups that have not historically been represented in research. One of our goals is to enroll a study population that aligns with the demographic makeup of myeloma patients in the U.S. Currently, 20% of U.S. myeloma patients are Black, and 15% are Hispanic.

Sham Mailankody, MD

Breaking New Ground in High-Risk Myeloma

The Horizon Two clinical trial is reimagining how we treat high-risk newly diagnosed multiple myeloma. We spoke with Dr. Sham Mailankody of Memorial Sloan Kettering (MSK) Cancer Center about what patients can expect — and why this moment marks a turning point in myeloma research.

Why do people with high-risk myeloma need different treatment options?

Over the past 25 years, treatments for multiple myeloma have improved a lot, especially for patients with what we call “standard-risk” disease. But people with high-risk myeloma haven’t seen those same benefits. About 1 in 4 newly diagnosed patients fall into this high-risk category, and unfortunately, these patients either do not respond to their initial therapy, or relapse within two years — whereas most patients are in remission for at least four or five years after their first therapy.

What is the Horizon Two trial, and how is it different from other studies?

Horizon Two is a national clinical trial created specifically for people who are newly diagnosed with high-risk myeloma. In the past, this group was often left out of research. The trial is designed to be flexible and patient-friendly. It allows multiple treatment options to be tested at once, and new ones can be added over time. Even patients who have already started their first cycle of treatment may still qualify. This approach helps us learn faster and include more people in the process.

What kinds of treatments are being tested in Horizon Two?

We’re looking at advanced treatments called immunotherapies — including CAR T-cell therapy and bispecific antibodies. These therapies have already worked well for patients with advanced or relapsed myeloma. Now we’re testing whether using them earlier, right after diagnosis, might lead to stronger and longer-lasting responses.

Will the trial consider how treatment affects patients’ quality of life?

Absolutely. Some treatment arms in the trial will explore time-limited therapy, meaning patients could stop treatment after a certain amount of time if they’re doing well. We’re also collecting direct feedback from patients and advocates to guide future parts of the study. Better treatment doesn’t just mean controlling the disease — it means improving how patients feel and live.

How is Horizon Two making it easier for more people to take part in research?

Horizon Two is available at many locations across the country — not just at large academic hospitals, but also at regional and community centers that work closely with myeloma experts. For example, patients don’t have to travel to Manhattan to take part in the trial at MSK; there may be a site closer to home. This setup helps reduce travel time and costs, making it easier for people, including those in rural or underserved areas, to access cutting-edge research and care.

How important is collaboration in making a study like this happen?

It’s absolutely necessary. Horizon Two is the result of years of collaboration through the MMRF and MMRC. It brings together top cancer centers, patient advocates, drug companies, and government regulators. Everyone plays a role: from designing the trial to enrolling patients. This kind of teamwork is what makes real progress possible.

What does success look like for Horizon Two?

Our biggest goal is to close the gap in outcomes between high-risk and standard-risk patients. If we can do that, we may one day no longer need the term “high-risk.” That would be a huge step forward for more effective treatments and for a more equitable future for everyone living with myeloma.

How Horizon Compares to Investigator- or Company-Sponsored Trials

The Horizon Clinical Trial Program is an innovative, efficient, and impactful way to test novel treatment strategies, inform further asset development, and guide future clinical practice.

Investigator-Sponsored Trial	MMRC-Sponsored Horizon Clinical Trial Program	Company-Sponsored Trial
• Single-arm study without a control	• Randomized trial with a control	• Randomized trial with a control
• Small, biased sample size across one or few sites	• Robust and representative sample size across 13 leading US sites	• Larger samples sizes across multiple sites
• Longer relative start-up time and patient accrual	• Accelerated start-up time and patient accrual	• Longer relative start-up time and variable patient accrual
• Lower relative cost	• Intermediate cost with efficiencies	• Higher relative cost and management requirement
Low impact; *not powered to make decisions or inform clinical practice*	***High impact;*** *powered to inform further drug development and clinical practice*	***High impact;*** *powered to support further drug development*



MMRF Virtual Lab®

One of the most significant barriers in medical and scientific research is lack of access to high-quality, large-scale data. Research efforts are often independent and disconnected: biopharma companies can't share data that would help competitors gain an edge above them, and academic researchers don't share data outside of their institution to protect their right to publish.

The MMRF has always been a leader in data-sharing, crossing boundaries to generate and disseminate data that has led to hundreds of scientific reports and publications that have both improved clinical strategies and helped drug development. We are expanding our impact with the launch of the MMRF Virtual Lab platform in fall 2025.

The MMRF Virtual Lab will be the largest, most comprehensive data-sharing and analytical platform in myeloma, available to researchers anywhere. The first-of-its kind online research environment will allow researchers to explore data from the MMRF and other myeloma studies, analyze findings, broaden their view of myeloma, ask better questions, and design better studies — all of which will accelerate new myeloma treatments. Researchers will be required to share their analyses so that we can continue to build the body of knowledge about myeloma and connect the community of experts working toward a cure.

All the data we generate through our landmark research projects, including the MMRF CoMMpass Study and Immune Atlas program, will ultimately be stored in Virtual Lab.

Our History of Data-Generating Initiatives

2004
Built the first multicenter tissue bank to enable large-scale research efforts.

2005
Created the first clinical consortium to advance innovative treatment approaches in the highest areas of unmet need for patients.

2008
Sequenced the myeloma genome to find new targets and biomarkers.

2011
Launched CoMMpass to understand how genomics influence prognosis and treatment outcomes.

2018
Launched the first platform drug trial in myeloma through MyDRUG™ to test the impact of several different drugs on different genetic mutations.

2019
Built on CoMMpass with the Immune Atlas program to better understand how a myeloma patient's immune system might change during disease progression and therapy.

2024
Introduced the Horizon Clinical Trials Program to test multiple novel therapy combinations to improve outcomes for myeloma patients.

2025
Today, we are harnessing the power of data with Virtual Lab — a groundbreaking global research platform offering comprehensive open-source data on myeloma.

Randy

was diagnosed with myeloma in June 2017. Cancer was sadly already part of Randy's story, having lost his daughter to breast cancer. **Seven years later, he has finally heard a word many patients long to hear : REMISSION.**

Thanks to the generosity of supporters like you, **the Multiple Myeloma Research Foundation** continues to drive tremendous impact for myeloma patients like Randy and Gail.

DONATE TODAY

Gail,

an attorney from Brooklyn with a passion for vintage fashion, has faced a tough journey as a refractory patient. **With support from the MMRF, she enrolled in a clinical trial testing a novel bispecific antibody.**

Learn more about Randy and Gail by visiting the MMRF's YouTube Channel.

Improving
Patient Outcomes

The MMRF exists to advance a cure for every single myeloma patient. We work to close gaps in access to quality care. Through our education and support programs, we help patients and caregivers get the information and resources they need to achieve the best possible outcomes.

In 2025 our 25 patient education programs reached over 16,000 people.

88%

reported taking positive steps to improve their care after participating in MMRF programs

66%

of patients reported feeling more confident discussing treatment options with their healthcare team

52%

of program participants gained a better understanding of their test results and planned to discuss them with their care team

Patient Education

The MMRF's education programs are designed to provide patients with the tools they need to advocate for the best care for their disease and improve their quality of life. From informational webinars to podcasts with leading experts in the myeloma field to community summits, our education programs reach over 16,000 people annually.

Earlier this year, we teamed up with Hackensack Meridian John Theurer Cancer Center and City of Hope for two MMRF Patient Summits, offering patients and their caregivers a platform to engage with top myeloma specialists, get their questions answered, and access valuable resources. These free summits are designed to be informative, engaging, and interactive, with opportunities for networking among patients and caregivers and connection with myeloma experts.

MMRF Patient Navigation Center

The MMRF Patient Navigation Center (PNC) is a free resource that helps patients and caregivers connect with Patient Navigators who can offer information and guidance through every step of the myeloma journey.

In April, the MMRF presented a poster at the 50th Annual Oncology Nursing Society (ONS) Congress, sharing the results of a survey evaluating the impact of the PNC. 86% of people who responded to the survey reported positive steps in myeloma care after communicating with an MMRF Patient Navigator.

At the Congress, the MMRF was honored to receive the 2025 ONS Outstanding Employer Award, which acknowledges employers whose exemplary support for their oncology nurses helps the team go above and beyond to engage with patients and their families.

> **"The MMRF patient navigators are extremely helpful and informative.** They helped me identify an additional clinical trial, which is personally a much better fit for what I want for myself. My anxiety was greatly reduced and I now have a forward path thanks to the wonderful team at MMRF." **—John M.**

Introducing the MMRF Chatbot

Have questions about multiple myeloma, the MMRF, or how to get involved? Our new chatbot is here to help guide you to information and resources along your myeloma journey. Visit our website and click the 'Chat Now' option at the bottom left of the page to try it.

> **“Thank you to the MMRF for organizing the event and putting this all on for the community.** It was great to hear all the different stories. All of the workers/ organizers were extremely friendly and helpful. I enjoyed seeing MMRF partnership with community organizations.”
>
> — **Kitty Wang,** MMRF LA Community Connect Attendee

MMRF Multiple Myeloma Community Connect

The MMRF partners with Acclinate’s NOWINCLUDED Community to host Multiple Myeloma Community Connect, a national event series designed to build relationships, share resources, and raise awareness in Black communities where there is a high incidence of myeloma. At these events we share information about treatment options, including clinical trials, with the goal of improving care and outcomes for every patient.

Each event features panel conversations with healthcare providers, caregivers, and myeloma patients. This year, Community Connect is coming to four cities: Los Angeles, Houston, Charlotte, and New Orleans.



88% felt inspired by this event to take actions toward their health or the health of their community

85% of attendees believe it is important to spread awareness of multiple myeloma in their community

68% of attendees left feeling more familiar with clinical research

57% of attendees shared that they have never discussed clinical research opportunities with their healthcare provider

Health Equity Summit

As part of our commitment to improving health outcomes for all myeloma patients, the MMRF holds an annual Health Equity Summit. These events bring together policymakers, academic researchers, biopharma executives, retail pharmacists, and community health advocates to identify strategies and best practices for improving equity and access in myeloma clinical research and care.

> **“Bringing different communities to the table is critical** — because not all medicines work the same way for everyone.”
>
> — **Robert Winn, MD**
> Director and Lipman Chair in Oncology,
> VCU Massey Comprehensive Cancer Center

Joselle Cook, MBBS, a 2023 MMRF Scholars Program Recipient, is investigating the prevalence of MGUS in underrepresented Black populations across the African diaspora — work that could uncover important biological drivers. Learn more by watching her video.

2024 RESEARCH SCHOLAR ANNOUNCEMENT

The MMRF Research Scholars Program provides financial support and mentorship for Black researchers and clinicians who are currently active or interested in pursuing a career in the field of myeloma and whose work includes efforts to advance health equity. Awardees are provided up to $400,000 over four years to support their career development and promote their myeloma projects. MMRF’s Research Scholars are building and expanding the myeloma research community, helping propel the field toward a cure. 2024 was our second year of awarding this program.

2024 RESEARCH SCHOLAR

Camille Edwards, MD
Boston Medical Center/ Boston University: *Mapping the molecular mechanisms of disease progression in MM and AL*

DONOR PROFILE

Jim Pass

Jim Pass is a myeloma patient and longtime supporter of the MMRF.
The former Senior Managing Director of Guggenheim Partners, Jim has built a career in financing, advising, and operating a diverse range of infrastructure assets, including airports, power plants, data centers, healthcare facilities, and student housing complexes. Jim and his wife Michelle have four adult children and split their time between Chicago and Naples, Florida.

Jim had never heard of multiple myeloma when he was diagnosed in 2020. Like many patients, he was stunned and terrified by the idea of living with cancer. As he and his family searched online for answers, his fear grew. But he came across one name that offered hope: the Multiple Myeloma Research Foundation.

Jim's diagnosis came suddenly. In February 2020, he found himself unable to stand without his wife Michelle's help. At the hospital, doctors discovered a lesion on his ribs and diagnosed him with myeloma. Within days, he began chemotherapy.

The MMRF connected Jim with myeloma specialists and helped him weigh his treatment options. They guided him to a clinical trial that was sponsored by the University of Chicago Medical Center and Endeavor Health that his doctor also agreed was a good fit. Between March 2020 and July 2022, Jim underwent treatment as part of that trial.

During this time, the COVID-19 pandemic was intensifying. Access to care was limited, travel was restricted, and support was suddenly out of reach.

Throughout Jim's treatment, the MMRF remained a steady source of support. The team helped Jim and his family understand complex medical information and navigate critical decisions. The MMRF's educational programs helped Jim learn more about his disease and the emotional support provided by the team helped his family stay grounded during the most difficult moments.

"The MMRF didn't just offer knowledge; they gave us hope and connection. We felt like we weren't going through it alone," Jim said.

Today, Jim continues regular monitoring with annual bone marrow and PET scans, along with quarterly blood tests. August 2025 marks three years in MRD (minimal residual disease). He credits the MMRF with helping him receive the best possible care.

"Thanks to the MMRF, we had choices — and we understood them," Jim said. **"Being able to walk into appointments prepared and with informed questions has been very empowering."**

Inspired by the support they received, Jim and his family have become dedicated MMRF donors and advocates. In 2020, Jim and his family joined a virtual walk to raise awareness and research funds for myeloma. Now, supporting MMRF has become a family mission, in particular for his 4 adult children, who have participated in various activities ranging from the MMRF Golf Invitational to running the Chicago Marathon with the MMRF's Team for Cures in addition to walking in the Chicago Walk/Run Annual Event.

His advice to others facing a diagnosis is simple but powerful: **"Keep an open mind — every journey is unique. Thanks to the MMRF there are more treatments, there are better treatments, and people are living longer. Accept your diagnosis, then shift your focus to getting better."**

2025
CALENDAR OF EVENTS

TEAM FOR CURES

August 31	TCS Sydney Marathon presented by ASICS	Sydney, Australia
September 5-15	Patient-Led Trek in the Dolomites	Bolzano, Italy
September 7	MMRF Walk/Run - Chicago	Chicago, IL
September 13	MMRF Walk/Run - Boston	Boston, MA
September 20	National Virtual Walk/Run	Virtual
September 20	MMRF Walk/Run - Twin Cities	St. Paul, MN
September 21	BMW Berlin Marathon	Berlin, Germany
September 27	MMRF Walk/Run - Washington, DC	Washington, D.C.
October 5	MMRF Walk/Run – Iowa City	Iowa City, IA
October 5-9	NH: White Mountains Glamping Adventure	Gorham, NH
October 11	MMRF Walk/Run – New York City	New York City, NY
October 12	Bank of America Chicago Marathon	Chicago, IL
October 18*	MMRF Walk/Run - Philadelphia	Philadelphia, PA
October 25*	MMRF Walk/Run - Atlanta	Atlanta, GA
October 26	Marine Corps Marathon	Arlington, VA
November 1*	MMRF Walk/Run – Houston	Houston, TX
November 2	TCS New York City Marathon	New York City, NY
November 5-9	Road to Victories: Ride for a Cure	Death Valley National Park, CA
November 15	MMRF Walk/Run – Los Angeles	Los Angeles, CA
November 22*	MMRF Walk/Run – Scottsdale	Scottsdale, AZ

PATIENT EDUCATION

August 27	Patient Livestream with MMRF PNC
September 24	Side Effects & Symptoms Patient Webinar
October 1	IMS Highlights Conference Highlights
October 8	Side Effects & Symptoms Patient Livestream
October 15	IMS Highlights Patient Livestream
October 11	Patient Summit in Partnership with UT Southwestern
November 19	Clinical Trials Patient Webinar
December 3	Clinical Trials Patient Livestream
December 17	ASH Highlights Conference Highlight

COMMUNITY CONNECT EVENTS

October TBD	Multiple Myeloma Community Connect	New Orleans

*Events are subject to change; for more information visit **themmrf.org**

Multiple Myeloma Research Foundation

383 Main Avenue, 7th Floor, Norwalk, CT 06851

Phone: 203-229-0464
Email: info@themmrf.org
Fax: 203-972-1259
Web: TheMMRF.org

Meet Alan C. Heitner, the MMRF's new CFO

What drew you to the MMRF?
I have devoted my career to not-for-profit financial management and was looking for my next opportunity to make an impact. When I was introduced to the MMRF and spent time on the website, it was clear that this organization has made an enormous impact, and I wanted to be a part of it.

What have you learned in your first six months as a part of this team and community?
In this brief time, it became clear to me how the MMRF has made such an impact. My colleagues on every level are wonderfully gifted people with a solitary focus on the mission. And the community goes above and beyond to spread knowledge and raise funds for patient support and research.

What have you found is different about the MMRF than other organizations you've worked with in the health space?
Our 360-degree approach to myeloma sets us apart. We provide 1:1 patient support, research emerging scientific hypotheses, sponsor an adaptive clinical trial program, and invest in promising startups with the potential to cure myeloma.

What financial principles guide the MMRF's commitment to being a trustworthy, high-impact organization?
Most MMRF funds are generously contributed by myeloma patients and people close to them. The MMRF is an outstanding steward of these contributed funds and ensures that the vast majority go directly to the mission of finding a cure for each and every myeloma patient.

Looking for guidance?

The MMRF is here to help. The professionals at our Patient Navigation Center can offer insights, counseling, and support throughout your treatment journey.

Give us a call, Mon–Fri 9am–7pm ET
888-841-6673

or email us at PatientNavigator@TheMMRF.org

MULTIPLE MYELOMA
Research Foundation

383 Main Avenue, 7th Floor
Norwalk, CT 06851

ABOUT THE MMRF

The Multiple Myeloma Research Foundation® (MMRF®) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception in 1998, the MMRF has raised over $600 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.

Adaptive biotechnologies Advancing MRD measurement. Empowering patient care.
ALEXION AstraZeneca Rare Disease
AMGEN
Baxter
Bristol Myers Squibb
Genentech A Member of the Roche Group
GSK
cure curetoday.com
Kite A GILEAD Company
ARCELLX
Johnson&Johnson
Pfizer
REGENERON
sanofi

CHARITY WATCH TOP-RATED
BEST IN AMERICA Certified by Independent Charities of America
Platinum Transparency 2025 Candid.
Charity Navigator